De-Risking Early-Stage Biotech: Turning Vision into Venture Capital
Insight Brief
Jul 03, 2025

Unlock the Blueprint for Smart Biotech Investment Decisions

In today's capital-constrained biotech landscape, early-stage companies must do more than innovate – they must strategically de-risk. This insight brief from IQVIA Biotech reveals how to transform your scientific vision into a compelling investment case that resonates with venture capitalists.

Download the insight brief to learn:

How to Build a Strategic Target Product Profile (TPP)
  • Align clinical and commercial goals from day one
  • Create a dynamic, evolving vision that adapts with evidence
  • Use TPPs to differentiate in crowded markets and accelerate timelines
How to Design a Clinical Development Plan (CDP) That Attracts Capital
  • Model multiple development pathways with real-world data
  • Balance time, cost, and risk to optimize ROI
  • Communicate clearly with investors using scenario-based planning
How to Use Expected Net Present Value (eNPV) to Quantify Opportunity
  • Translate scientific uncertainty into investor-ready metrics
  • Compare development strategies with a single, objective value lens
  • Leverage scenario modeling to show trade-offs and upside potential
Whether you're preparing for Series A or planning your next round, this guide will help you:
  • Prioritize high-value indications
  • Align internal teams and external stakeholders
  • Build confidence with investors through robust, data-driven planning
You may also be interested in